Dr Harry Parekh, chief research officer for PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF), tells Proactive's Andrew Scott they've hit a number of key milestones with their Sol-gel program.
He says they've now successfully optimised the conditions for extracting cannabinoids from one of their cannabis strains … ''we've also quantified how much of each of those cannabinoids are present within that extract and it falls well within the range of what the provider of that cannabis strain specified to us'', he adds.
''We're very confident now moving forward, developing a standard operating procedure to extract it from the remaining four strains''.
Original Article: PreveCeutical Medical making key advances with its Sol-gel program